Publications :: OPKO Health, Inc. (OPK)

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Read the news release

Visit BioReference Health

PubMed

Oct 7, 2021

Extended-release calcifediol in stage 3-4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D

Nature Cancer

Nov 15, 2019

Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation

PubMed

Nov 7, 2019

Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD)

PubMed

Mar 28, 2019

Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease

PubMed

Sep 28, 2017

Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease

Science

Sep 15, 2017

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

PubMed

Sep 7, 2017

Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease

PubMed

Sep 28, 2016

Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease

Karger

Jan 28, 2015

Modified-Release Calcifediol Effectively Controls Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease

PubMed

Nov 28, 2014

Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation

Select a page